IL290974A - Methods and compositions for improving oncolytic virus infection for non-permissive cancer - Google Patents
Methods and compositions for improving oncolytic virus infection for non-permissive cancerInfo
- Publication number
- IL290974A IL290974A IL290974A IL29097422A IL290974A IL 290974 A IL290974 A IL 290974A IL 290974 A IL290974 A IL 290974A IL 29097422 A IL29097422 A IL 29097422A IL 290974 A IL290974 A IL 290974A
- Authority
- IL
- Israel
- Prior art keywords
- nonpermissive
- cancers
- compositions
- methods
- virus infection
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 244000309459 oncolytic virus Species 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962894929P | 2019-09-02 | 2019-09-02 | |
| US201962913667P | 2019-10-10 | 2019-10-10 | |
| PCT/US2020/048932 WO2021046048A1 (en) | 2019-09-02 | 2020-09-01 | Methods and compositions for improving oncolytic virus infection for nonpermissive cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL290974A true IL290974A (en) | 2022-05-01 |
Family
ID=74853433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL290974A IL290974A (en) | 2019-09-02 | 2022-02-28 | Methods and compositions for improving oncolytic virus infection for non-permissive cancer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12691151B2 (enExample) |
| EP (1) | EP4025230B1 (enExample) |
| JP (2) | JP2022546985A (enExample) |
| KR (1) | KR20220054865A (enExample) |
| CN (1) | CN114667154A (enExample) |
| AU (1) | AU2020340934A1 (enExample) |
| CA (1) | CA3152787A1 (enExample) |
| IL (1) | IL290974A (enExample) |
| WO (1) | WO2021046048A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202100305SA (en) | 2018-07-13 | 2021-02-25 | Univ Arizona State | Methods of treating cancer with tnf expressing myxoma virus |
| WO2020033510A1 (en) | 2018-08-08 | 2020-02-13 | Arizona Board Of Regents On Behalf Of Arizona State University | Method for improved poxvirus yields |
| CA3112788A1 (en) | 2018-09-05 | 2020-03-12 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic virus platform to treat hematological cancer |
| CA3152787A1 (en) | 2019-09-02 | 2021-03-11 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions for improving oncolytic virus infection for nonpermissive cancers |
| CN114615988A (zh) | 2019-09-02 | 2022-06-10 | 亚利桑那州立大学董事会 | 用黏液瘤病毒治疗癌症的新型溶瘤病毒平台 |
| CN116077505B (zh) * | 2023-01-17 | 2024-09-06 | 广东省人民医院 | Kpt-330联合5-fu或奥沙利铂在抗胃癌肿瘤药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2431349A1 (en) | 2002-06-06 | 2003-12-06 | Xiao-Dan Yao | Method of producing a recombinant virus |
| WO2004015118A1 (en) | 2002-08-07 | 2004-02-19 | Bavarian Nordic A/S | Vaccinia virus host range genes to increase the titer of avipoxviruses |
| AU2003264144C1 (en) | 2002-09-05 | 2009-12-17 | Bavarian Nordic A/S | Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions |
| DK2388315T3 (da) | 2005-03-07 | 2014-08-25 | Univ Western Ontario | Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling |
| US20120100109A1 (en) * | 2010-10-26 | 2012-04-26 | Xiaoliu Zhang | Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors |
| WO2015103438A2 (en) * | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| WO2020033510A1 (en) | 2018-08-08 | 2020-02-13 | Arizona Board Of Regents On Behalf Of Arizona State University | Method for improved poxvirus yields |
| CA3152787A1 (en) | 2019-09-02 | 2021-03-11 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions for improving oncolytic virus infection for nonpermissive cancers |
-
2020
- 2020-09-01 CA CA3152787A patent/CA3152787A1/en active Pending
- 2020-09-01 WO PCT/US2020/048932 patent/WO2021046048A1/en not_active Ceased
- 2020-09-01 CN CN202080076789.2A patent/CN114667154A/zh active Pending
- 2020-09-01 EP EP20861619.3A patent/EP4025230B1/en active Active
- 2020-09-01 KR KR1020227010864A patent/KR20220054865A/ko not_active Ceased
- 2020-09-01 US US17/639,563 patent/US12691151B2/en active Active
- 2020-09-01 AU AU2020340934A patent/AU2020340934A1/en not_active Abandoned
- 2020-09-01 JP JP2022513552A patent/JP2022546985A/ja active Pending
-
2022
- 2022-02-28 IL IL290974A patent/IL290974A/en unknown
-
2024
- 2024-10-31 JP JP2024192261A patent/JP2025028853A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021046048A1 (en) | 2021-03-11 |
| AU2020340934A1 (en) | 2022-03-31 |
| EP4025230A4 (en) | 2023-10-04 |
| JP2025028853A (ja) | 2025-03-05 |
| CA3152787A1 (en) | 2021-03-11 |
| US12691151B2 (en) | 2026-07-28 |
| JP2022546985A (ja) | 2022-11-10 |
| KR20220054865A (ko) | 2022-05-03 |
| EP4025230B1 (en) | 2025-11-05 |
| EP4025230A1 (en) | 2022-07-13 |
| US20220296660A1 (en) | 2022-09-22 |
| CN114667154A (zh) | 2022-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276341A (en) | Methods and compositions for bypassing virus antibody vectors | |
| GB2592769B (en) | CpG-Adjuvanted SARS-CoV-2 virus vaccine | |
| IL257384A (en) | Preparations containing rnai and their use for the treatment of infection with the hepatitis b virus | |
| IL290792A (en) | Compositions and methods for the treatment of viral infections | |
| EP3139954A4 (en) | Methods and compositions for treating hepatitis b virus infections | |
| GB202209657D0 (en) | On-ear detection | |
| ZA202202370B (en) | Compositions and methods for treating viral infections | |
| ZA202007649B (en) | Virus and antigen purification and conjugation | |
| IL270989A (en) | Oncolytic virus and method | |
| IL262579A (en) | Compounds and methods for treating viral infection in shrimp | |
| EP3468593A4 (en) | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING A ZIKA VIRUS INFECTION | |
| IL285232A (en) | Preparations containing oleandrin for the treatment of viral infection | |
| IL290923A (en) | Antibody preparations and methods for treating hepatitis b virus infection | |
| EP4025230A4 (en) | Methods and compositions for improving oncolytic virus infection for nonpermissive cancers | |
| EP3927838A4 (en) | METHODS AND COMPOSITIONS FOR THE EARLY DETECTION OF CANCER | |
| EP3250553A4 (en) | Compositions and methods for inhibiting viral infection | |
| EP3875119A4 (en) | ONCOLYTIC VIRUS FOR CANCER THERAPY | |
| IL312450A (en) | Methods and compositions for protein detection | |
| GB201816547D0 (en) | Oncolytic virus for the treatment of cancer | |
| IL279435A (en) | Methods and preparations for detecting a somatic variant | |
| ZA202201079B (en) | Compositions and methods useful for ebola virus infection | |
| SG11202108262VA (en) | Bacterialcidal methods and compositions | |
| PL3810625T3 (pl) | Sposoby i kompozycje do leczenia zakażenia wirusem zapalenia wątroby typu b | |
| HK40073290A (en) | Antibody compositions and methods for treating hepatitis b virus infection | |
| HK40076807A (en) | Compositions and methods for treating viral infections |